Rezolute Inc. (RZLT)
NASDAQ: RZLTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 12:53 PM ET
RZLT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $436.22M
- EPS (TTM)
- -$0.75
- Dividend yield
- None
- 52-week range
- 1.07 – 11.46
- Day range
- 4.33 – 4.54
- Volume / Avg
- 596.56K / 1.48M
- Beta
- —
- Shares outstanding
- 96.72M
- Next earnings
- Nov 5, 2026
52-week range
RZLT stock today
On Oct 8, RZLT is trading at $4.51, adding $0.13 (2.97%), versus the S&P 500's 0.52% decline. At this level, RZLT sits in the middle of its 52-week range of $1.07 to $11.46: 60.6% below the high, set on Nov 10, 2025 and 321.5% above the low. RZLT is up 85.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 50.0%.
Rezolute has posted a net loss over the last twelve months (EPS of -$0.75), so its P/E ratio is not meaningful. Rezolute's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Rezolute
Company profileRezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Nevan Charles Elam J.D.
- Headquarters
- Redwood City, CA
- Employees
- 58
- Website
- rezolutebio.com
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$9.80+117.29%
- Strong buy 2
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.18
Rezolute peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DMACDiaMedica Therapeutics Inc. | 7.72 | -3.38% | $416.31M | vs RZLT |
| AVIRAtea Pharmaceuticals Inc. | 5.11 | +2.00% | $409.85M | vs RZLT |
| PRTAProthena Corporation plc | 8.55 | +0.78% | $438.73M | vs RZLT |
| SPRYARS Pharmaceuticals Inc. | 4.45 | +2.06% | $442.54M | vs RZLT |
| KMDAKamada Ltd. | 7.71 | -2.28% | $444.95M | vs RZLT |
| OVIDOvid Therapeutics Inc. | 2.31 | -2.34% | $450.16M | vs RZLT |
| ASMBAssembly Biosciences Inc. | 22.30 | -2.83% | $454.04M | vs RZLT |
| CAPRCapricor Therapeutics Inc. | 8.00 | -1.30% | $464.82M | vs RZLT |
Indexes, lists and sector
Rezolute stock FAQ
What is Rezolute's stock price today?
RZLT last traded at $4.51 as of Oct 8, 12:53 PM EDT, up 2.97% on the day. Prices are delayed at least 15 minutes.
Does Rezolute pay a dividend?
No. Rezolute does not currently pay a regular cash dividend.
When is Rezolute's next earnings date?
Rezolute is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.18.
Who is Rezolute's CEO?
Mr. Nevan Charles Elam J.D. is the chief executive officer of Rezolute Inc., which has about 58 employees.
Has RZLT ever split its stock?
Yes. The most recent RZLT stock split was a 1-for-50 split on Oct 13, 2020, one of 2 splits on record.
What is the RZLT 52-week high?
The 52-week high for RZLT is $11.46 and the 52-week low is $1.07. The stock is currently 60.6% below its high.